April 01, 2021 | Featured
London, UK. April 1st 2021.
Intract Pharma Limited today announced the initiation of a collaborative research programme with Ferring Pharmaceuticals, to investigate oral delivery of a monoclonal antibody (mAb) targeting an undisclosed interleukin for treatment of inflammatory bowel disease (IBD). The research will focus on evaluation of Intract’s Phloral® and Soteria® technologies for precision oral delivery of the therapeutic mAb directly to GI tissue to improve efficacy and minimize systemic exposure.
Commenting on the collaboration, Bill Lindsay, Intract’s CEO, said “Intract’s technologies are unique in terms of precision targeting of biologic drugs, especially mAbs, via the oral route allowing the possibility for localized treatment of GI diseases without the risk of serious adverse effects resulting from high dose injections. We are excited to enter this collaboration with Ferring which has a long heritage in gastroenterology products and a commitment to continuous innovation for new therapies for patients suffering from chronic GI diseases”.
About Intract Pharma
Intract Pharma is a company which specializes in oral drug delivery, developing state-of-the-art formulation technologies and unique gastrointestinal models to develop advanced new therapeutics. Since its inception, Intract has pursued innovation in oral drug delivery as a means to improve on current therapies, making them safer and more effective for patients. The drug delivery technologies Phloral® for precise colonic drug delivery, and Soteria® for delivery of biotherapeutics to gastrointestinal tissue, are available for license exclusively from Intract Pharma. For more information visit www.intractpharma.com
Copyright © 2018 Intract Pharma
A site by: Web Design London